Literature DB >> 27192568

Co-stimulatory and Co-inhibitory Pathways in Autoimmunity.

Qianxia Zhang1, Dario A A Vignali2.   

Abstract

The immune system is guided by a series of checks and balances, a major component of which is a large array of co-stimulatory and co-inhibitory pathways that modulate the host response. Although co-stimulation is essential for boosting and shaping the initial response following signaling through the antigen receptor, inhibitory pathways are also critical for modulating the immune response. Excessive co-stimulation and/or insufficient co-inhibition can lead to a breakdown of self-tolerance and thus to autoimmunity. In this review, we will focus on the role of co-stimulatory and co-inhibitory pathways in two systemic (systemic lupus erythematosus and rheumatoid arthritis) and two organ-specific (multiple sclerosis and type 1 diabetes) emblematic autoimmune diseases. We will also discuss how mechanistic analysis of these pathways has led to the identification of potential therapeutic targets and initiation of clinical trials for autoimmune diseases, as well as outline some of the challenges that lie ahead.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27192568      PMCID: PMC4873959          DOI: 10.1016/j.immuni.2016.04.017

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  196 in total

1.  CD40 on NOD CD4 T cells contributes to their activation and pathogenicity.

Authors:  Rocky L Baker; David H Wagner; Kathryn Haskins
Journal:  J Autoimmun       Date:  2008-10-31       Impact factor: 7.094

2.  4-1BB triggering ameliorates experimental autoimmune encephalomyelitis by modulating the balance between Th17 and regulatory T cells.

Authors:  Young H Kim; Beom K Choi; Su M Shin; Chang H Kim; Ho S Oh; Sang H Park; Don G Lee; Myoung J Lee; Kwang H Kim; Dass S Vinay; Byoung S Kwon
Journal:  J Immunol       Date:  2011-06-29       Impact factor: 5.422

3.  Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease.

Authors:  Laurent Monney; Catherine A Sabatos; Jason L Gaglia; Akemi Ryu; Hanspeter Waldner; Tatyana Chernova; Stephen Manning; Edward A Greenfield; Anthony J Coyle; Raymond A Sobel; Gordon J Freeman; Vijay K Kuchroo
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

4.  OX40 Ligand Contributes to Human Lupus Pathogenesis by Promoting T Follicular Helper Response.

Authors:  Clément Jacquemin; Nathalie Schmitt; Cécile Contin-Bordes; Yang Liu; Priya Narayanan; Julien Seneschal; Typhanie Maurouard; David Dougall; Emily Spence Davizon; Hélène Dumortier; Isabelle Douchet; Loïc Raffray; Christophe Richez; Estibaliz Lazaro; Pierre Duffau; Marie-Elise Truchetet; Liliane Khoryati; Patrick Mercié; Lionel Couzi; Pierre Merville; Thierry Schaeverbeke; Jean-François Viallard; Jean-Luc Pellegrin; Jean-François Moreau; Sylviane Muller; Sandy Zurawski; Robert L Coffman; Virginia Pascual; Hideki Ueno; Patrick Blanco
Journal:  Immunity       Date:  2015-06-09       Impact factor: 31.745

5.  The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells.

Authors:  Peter T Sage; Alison M Paterson; Scott B Lovitch; Arlene H Sharpe
Journal:  Immunity       Date:  2014-12-05       Impact factor: 31.745

6.  Anti-4-1BB-based immunotherapy for autoimmune diabetes: lessons from a transgenic non-obese diabetic (NOD) model.

Authors:  Huey-Kang Sytwu; Wen-Der Lin; Steve R Roffler; Jung-Tung Hung; Hsiang-Sheng Sung; Chi-Hsien Wang; Tian-Lu Cheng; Shey-Cherng Tsou; Sheng-Chuan Hsi; Kuo-Liang Shen
Journal:  J Autoimmun       Date:  2003-11       Impact factor: 7.094

7.  CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice.

Authors:  Juergen Foell; Simona Strahotin; Shawn P O'Neil; Megan M McCausland; Carolyn Suwyn; Michael Haber; Praveen N Chander; Abhijit S Bapat; Xiao-Jie Yan; Nicholas Chiorazzi; Michael K Hoffmann; Robert S Mittler
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

8.  Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells.

Authors:  Hélène Bour-Jordan; Benoît L Salomon; Heather L Thompson; Gregory L Szot; Matthew R Bernhard; Jeffrey A Bluestone
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

9.  Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis.

Authors:  Bing Zhu; Indira Guleria; Arezou Khosroshahi; Tanuja Chitnis; Jaime Imitola; Miyuki Azuma; Hideo Yagita; Mohamed H Sayegh; Samia J Khoury
Journal:  J Immunol       Date:  2006-03-15       Impact factor: 5.422

10.  Prevention of diabetes in NOD mice at a late stage by targeting OX40/OX40 ligand interactions.

Authors:  Syamasundar V Pakala; Pratima Bansal-Pakala; Beth S Halteman; Michael Croft
Journal:  Eur J Immunol       Date:  2004-11       Impact factor: 5.532

View more
  86 in total

Review 1.  Cytokines and costimulation in acute graft-versus-host disease.

Authors:  Geoffrey R Hill; Motoko Koyama
Journal:  Blood       Date:  2020-07-23       Impact factor: 22.113

2.  Autoimmunity and Cancer, the Paradox Comorbidities Challenging Therapy in the Context of Preexisting Autoimmunity.

Authors:  Julio C Valencia; Nkolika Egbukichi; Rebecca A Erwin-Cohen
Journal:  J Interferon Cytokine Res       Date:  2018-12-18       Impact factor: 2.607

Review 3.  Inhibitory receptor agonists: the future of autoimmune disease therapeutics?

Authors:  Stephanie Grebinoski; Dario Aa Vignali
Journal:  Curr Opin Immunol       Date:  2020-06-30       Impact factor: 7.486

4.  Multivalent Soluble Antigen Arrays Exhibit High Avidity Binding and Modulation of B Cell Receptor-Mediated Signaling to Drive Efficacy against Experimental Autoimmune Encephalomyelitis.

Authors:  Brittany L Hartwell; Chad J Pickens; Martin Leon; Cory Berkland
Journal:  Biomacromolecules       Date:  2017-05-17       Impact factor: 6.988

Review 5.  Immune checkpoint dysfunction in large and medium vessel vasculitis.

Authors:  Ryu Watanabe; Hui Zhang; Gerald Berry; Jörg J Goronzy; Cornelia M Weyand
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-03-17       Impact factor: 4.733

6.  TFH cells depend on Tcf1-intrinsic HDAC activity to suppress CTLA4 and guard B-cell help function.

Authors:  Fengyin Li; Xin Zhao; Yali Zhang; Peng Shao; Xiaoke Ma; William J Paradee; Chengyu Liu; Jianmin Wang; Hai-Hui Xue
Journal:  Proc Natl Acad Sci U S A       Date:  2021-01-12       Impact factor: 11.205

7.  CD28 Signaling Controls Metabolic Fitness of Pathogenic T Cells in Medium and Large Vessel Vasculitis.

Authors:  Hui Zhang; Ryu Watanabe; Gerald J Berry; Steven G Nadler; Jörg J Goronzy; Cornelia M Weyand
Journal:  J Am Coll Cardiol       Date:  2019-04-16       Impact factor: 24.094

Review 8.  The immunoinhibitory PD-1/PD-L1 pathway in inflammatory blood vessel disease.

Authors:  Cornelia M Weyand; Gerald J Berry; Jörg J Goronzy
Journal:  J Leukoc Biol       Date:  2017-12-29       Impact factor: 4.962

9.  The CD137 Ligand Is Important for Type 1 Diabetes Development but Dispensable for the Homeostasis of Disease-Suppressive CD137+ FOXP3+ Regulatory CD4 T Cells.

Authors:  Bardees M Foda; Ashley E Ciecko; David V Serreze; William M Ridgway; Aron M Geurts; Yi-Guang Chen
Journal:  J Immunol       Date:  2020-04-15       Impact factor: 5.422

Review 10.  The promise and challenges of immune agonist antibody development in cancer.

Authors:  Patrick A Mayes; Kenneth W Hance; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2018-06-15       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.